Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘CD25’

Highlights and commentary on key AACR21 data presentations

It’s time for some commentary and insights regarding important emerging data from the AACR meeting.

The route to success in oncology R&D is always paved with gold, after all, although big ticket acquisitions may take some of the sting out of the tail.

As always, there were some hidden gems in the AACR21 program — in the first of our post meeting critiques, we take a careful look at the what’s behind the veneer.

We have a round baker’s dozen of early new product development compounds and explore them all to find out what interesting, as well as where there are potential pointers for future challenges which may need to be addressed…

To learn more about the AACR21 data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Looking through the window at some novel new product development concepts in oncology

Not in San Diego – What we wanted to explore in this post was some nice examples of either creative thinking outside the box or where researchers have challenged existing dogma and revealed some intriguing or unexpected findings. These are all examples from talks or posters showcased yesterday during the second AACR virtual meeting…

We take a look at several quite different approaches, which may either turn out to be useful new agents in clinical development, new targets, or even some unexpected tweaks in clinical trial design based on emerging evidence on the biology side that may lead to a new understanding in an area where previous attempts failed to yield a positive result…

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the second AACR meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Could targeting Regulatory T cells be a game changer?

Casa Milà, Barcelona

One of the pleasures of going to international cancer immunotherapy conferences is the opportunity to meet great scientists such as Sergio Quezada, PhD. He’s a Professor of Cancer Immunology and Immunotherapy at University College London (UCL) Cancer Institute.

After his PhD, he joined the laboratory of Jim Allison at MSKCC in 2004, and as we heard from Nobel Laureate Sir Richard Roberts FRS on the last episode of the Novel Targets Podcast, working in the laboratory of a future Nobel Laureate is one of his 10 tongue in cheek suggestions to improve your chances of winning a Nobel prize!

Professor Quezada kindly spoke to BSB last week at the European Association for Cancer Research (EACR) “Defense is the Best Attack” conference.

In Barcelona, we talked about the research done by his UCL group into regulatory T cells (Tregs) that led to the development of a novel first-in-class Treg depleting anti-CD25 antibody.

As Prof Quezada told BSB:

“This was the dream. It was basic biology, a big curiosity, lots of basic biology and being very stubborn and lots of luck. And now we have something that came out of PhD students and postdocs that some medic or nurse is gonna be injecting at the end of the year into a patient, so it’s really exciting. It’s really, really exciting!”

We enjoyed talking with Prof Quezada and appreciated the perspicacious insights he shared on where we’ve come from and where we may be going.

If you’d like to read more about the science and potential for this approach in cancer immunotherapy, subscribers can log-in to read our latest thought leader interview or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!